EDWARDS JEFFREY L
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Lifecore Biomedical to be acquired by Webster Equity Partners. Lifecore Biomedical has announced it will be acquired by Webster Equity Partners in a deal valued at up to $663.7 million. Shareholders may receive up to $9.67 per common equivalent, combining cash and contingent value rights based on performance milestones. This transaction is significant as it represents a full exit for the company, with the potential payout exceeding the current average analyst target of $6.75.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Kyntra Bio Names Andrew Singer to Board. Kyntra Bio has added Andrew E. Singer, MBA, to its board of directors. The move expands the company’s leadership team and could bring new expertise to its strategic planning. The appointment follows the company’s ongoing efforts to strengthen governance and support its growth initiatives. Investors may view the change as a sign of continued focus on development and operational improvement.
Transaction History
| BIO | ▲ Buy | Option Exercise | 407 | $0 | 4/21/2026 | View on chart |
| BIO | ▲ Buy | Option Exercise | 308 | $0 | 4/22/2025 | View on chart |
| LFCR | ▲ Buy | Grant | 30,000 | — | 7/8/2024 | View on chart |
| LFCR | ▲ Buy | Option Exercise | 9,554 | — | 2/1/2024 | View on chart |
| KYNB | ▼ Sell | Open Market | 3,265 | $55K | 6/9/2023 | View on chart |
| KYNB | ▼ Sell | Open Market | 4,624 | $81K | 6/9/2023 | View on chart |
| KYNB | ▲ Buy | Grant | 8,289 | $0 | 6/7/2023 | View on chart |
| LFCR | ▲ Buy | Grant | 18,182 | — | 6/1/2023 | View on chart |
| LFCR | ▲ Buy | Option Exercise | 9,474 | — | 5/31/2023 | View on chart |
| KYNB | ▲ Buy | Grant | 15,777 | $0 | 6/16/2022 | View on chart |
| LFCR | ▲ Buy | Grant | 7,059 | $67K | 6/4/2022 | View on chart |
| LFCR | ▲ Buy | Grant | 5,398 | $53K | 10/14/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Bio‑Rad Leads in Recombinant Protein & Magnetic Bead Growth
The latest market report shows the recombinant protein manufacturing sector is expected to triple in revenue by 2030, with Bio‑Rad listed among the key players. A separate analysis projects the magnetic bead market to grow from $3.3 billion in 2025 to $7.4 billion by 2032, again naming Bio‑Rad as a leader. These developments highlight the company’s expanding role in both protein production and diagnostic reagent markets.
Bio‑Rad Leads in Recombinant Protein & Magnetic Bead Growth. The latest market report shows the recombinant protein manufacturing sector is expected to triple in revenue by 2030, with Bio‑Rad listed among the key players. A separate analysis projects the magnetic bead market to grow from $3.3 billion in 2025 to $7.4 billion by 2032, again naming Bio‑Rad as a leader. These developments highlight the company’s expanding role in both protein production and diagnostic reagent markets.